238 related articles for article (PubMed ID: 30983472)
21. The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: An observational analysis.
Zheng Y; Tormey CA
Transfus Med; 2020 Aug; 30(4):304-307. PubMed ID: 32342588
[TBL] [Abstract][Full Text] [Related]
22. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
[TBL] [Abstract][Full Text] [Related]
23. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.
Maguire M; Fuh L; Goldstein JN; Marshall AL; Levine M; Howell ML; Parry BA; Rosovsky R; Hayes BD
West J Emerg Med; 2019 Jul; 20(4):619-625. PubMed ID: 31316701
[TBL] [Abstract][Full Text] [Related]
24. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal.
Makhoul T; Kelly G; Kersten B; Nadler M; Zammit CG; Jones CMC; Scott R; Acquisto NM
Thromb Res; 2020 Oct; 194():158-164. PubMed ID: 32788109
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
26. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
[TBL] [Abstract][Full Text] [Related]
27. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
29. Three-Factor Versus Four-Factor Prothrombin Complex Concentrate for the Emergent Management of Warfarin-Associated Intracranial Hemorrhage.
Fischer D; Sorensen J; Fontaine GV
Neurocrit Care; 2018 Feb; 28(1):43-50. PubMed ID: 28612131
[TBL] [Abstract][Full Text] [Related]
30. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
[TBL] [Abstract][Full Text] [Related]
31. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
32. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
[TBL] [Abstract][Full Text] [Related]
33. The Association of ICH Exclusion Criteria With Mortality and Disability Rates in ICH Patients Receiving 4F-PCC for Anticoagulation Reversal.
Zaeem M; Porter BA; Delibert S; Jones CMC; Acquisto NM
Ann Pharmacother; 2021 May; 55(5):605-610. PubMed ID: 32969238
[TBL] [Abstract][Full Text] [Related]
34. Prothrombin complex concentrate administration timing in warfarin-associated intracranial hemorrhage.
Townsend B; Slechta J; Gilbert BW
Am J Emerg Med; 2024 Feb; 76():136-139. PubMed ID: 38071882
[TBL] [Abstract][Full Text] [Related]
35. Hemostatic Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in Doac-Associated Intracranial Hemorrhage.
Whaley PM; Franco-Martinez C; Lock AE; Ramaswamy D; Young EH; Allen SM; Barthol CA
J Pharm Pract; 2024 Jun; 37(3):557-562. PubMed ID: 36564900
[No Abstract] [Full Text] [Related]
36. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
Reynolds TR; Gilbert BW; Hall KM
J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
[TBL] [Abstract][Full Text] [Related]
37. Utilization and safety of off-label prothrombin complex concentrate (4F-PCC) in a nonsurgical population.
Sandquist K; Kaucher K; Newell J; Sarangarm P; Burnett A
Blood Coagul Fibrinolysis; 2024 Jun; 35(4):161-166. PubMed ID: 38477829
[TBL] [Abstract][Full Text] [Related]
38. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
39. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series.
Bradshaw PG; Keegan S; Foertsch M; Yang GL; Ngwenya LB; Srinivasan V
J Thromb Thrombolysis; 2022 Aug; 54(2):295-300. PubMed ID: 35507109
[TBL] [Abstract][Full Text] [Related]
40. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
Go AS; Leong TK; Sung SH; Wei R; Harrison TN; Gupta N; Baker N; Goldstein B; Ataher Q; Solomon MD; Reynolds K;
J Thromb Thrombolysis; 2022 Oct; 54(3):470-479. PubMed ID: 35984591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
